Aquestive Therapeutics (AQST) Depreciation & Amortization (CF) (2017 - 2026)

Aquestive Therapeutics' Depreciation & Amortization (CF) history runs 10 years deep, the most recent figure standing at $113000.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 18.71% year-over-year to $113000.0 in Q1 2026; TTM through Mar 2026 was $522000.0, a 19.69% decrease from a year earlier, with the FY2025 full-year figure at $548000.0, down 23.68% from the prior year.
• Depreciation & Amortization (CF) slipped to $113000.0 in Q1 2026 per AQST's latest filing, from $130000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $727000.0 in Q1 2022 and bottomed at $113000.0 in Q1 2026.
• The 5-year median for Depreciation & Amortization (CF) is $207000.0 (2024), against an average of $300647.1.
• Across the five-year window, Depreciation & Amortization (CF) increased 17.63% in 2023 and slumped 68.52% in 2024, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $397000.0 in 2022, then grew by 17.63% to $467000.0 in 2023, then plunged by 68.52% to $147000.0 in 2024, then slipped by 11.56% to $130000.0 in 2025, then dropped by 13.08% to $113000.0 in 2026.
• Per Business Quant, the three latest AQST Depreciation & Amortization (CF) figures stand at $113000.0 (Q1 2026), $130000.0 (Q4 2025), and $139000.0 (Q3 2025).